Clinical Trial

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-10-21; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-16
Status change: Recruiting → Not Yet Recruiting 2025-12-10
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07220616
Lead Sponsor Daiichi Sankyo
Conditions Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Enrollment 420 participants
Start Date 2026-01-16
Primary Completion 2030-11-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-09